Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer

Executive Summary

The event that the oncology market has been waiting for has arrived. FDA approved Merck’s PD-1 inhibitor Keytruda for first-line treatment of non-small cell lung cancer, a paradigm-changing event that opens up the largest sales segment for immuno-oncology.

Advertisement

Related Content

Combinations Continue To Drive Immuno-Oncology Deal-Making
Tumor Mutation Burden Biomarker Emerges In Bristol's '026 Lung Cancer Post Mortem
Bristol Changes Up R&D But Not Backing Down On Oncology
BMS M&A Q&A: Is IO Player Now In Play? Lung Cancer Moves Seen As Key
NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
Keeping Track: Arymo ER Approved, Parsabiv Returns, Merck Surprises With Keytruda Chemo Combo Submission
Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval
Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology
'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097532

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel